NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Advaxis Inc., (OTCBB: ADXS), a developmental biotechnology company, received comments from the U. S. Food & Drug Administration (the “FDA”) regarding its Investigational New Drug (“IND”) application for Lovaxin C, the Company’s lead drug candidate, which was filed with a proposed Phase II study for the treatment of Cervical Intraepithelial Neoplasia (“CIN”).
